NASDAQ:DBVT DBV Technologies (DBVT) Stock Price, News & Analysis $9.00 +0.49 (+5.76%) Closing price 08/1/2025 03:58 PM EasternExtended Trading$9.03 +0.03 (+0.33%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About DBV Technologies Stock (NASDAQ:DBVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DBV Technologies alerts:Sign Up Key Stats Today's Range$8.80▼$9.5450-Day Range$7.74▼$11.5452-Week Range$2.20▼$12.78Volume24,525 shsAverage Volume26,058 shsMarket Capitalization$246.51 millionP/E RatioN/ADividend YieldN/APrice Target$14.75Consensus RatingModerate Buy Company Overview DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. Read More DBV Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreDBVT MarketRank™: DBV Technologies scored higher than 73% of companies evaluated by MarketBeat, and ranked 254th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDBV Technologies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DBV Technologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($7.05) to ($5.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently decreased by 23.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.05% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently decreased by 23.37%, indicating that investor sentiment is improving significantly. News and Social Media0.9 / 5News Sentiment-0.39 News SentimentDBV Technologies has a news sentiment score of -0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for DBV Technologies this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for DBVT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,761.00 in company stock.Percentage Held by InsidersOnly 1.44% of the stock of DBV Technologies is held by insiders.Percentage Held by Institutions71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DBV Technologies' insider trading history. Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DBVT Stock News HeadlinesDBV Technologies S.A.: DBV Technologies Reports Second Quarter and Half-Year 2025 Financial ResultsJuly 30 at 4:52 AM | finanznachrichten.deDBV Technologies Reports Progress in Clinical Trials and FinancingJuly 29, 2025 | tipranks.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.August 2 at 2:00 AM | Weiss Ratings (Ad)DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the ReportJuly 29, 2025 | globenewswire.comDBV Technologies Reports Second Quarter and Half-Year 2025 Financial ResultsJuly 29, 2025 | globenewswire.comHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFJuly 28, 2025 | globenewswire.comDBV Technologies (DBVT) Projected to Post Quarterly Earnings on TuesdayJuly 27, 2025 | americanbankingnews.comDBV Technologies Announces Appointment of James Briggs as Chief Human Resources OfficerJuly 22, 2025 | globenewswire.comSee More Headlines DBVT Stock Analysis - Frequently Asked Questions How have DBVT shares performed this year? DBV Technologies' stock was trading at $3.09 at the beginning of the year. Since then, DBVT stock has increased by 191.3% and is now trading at $9.00. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) announced its quarterly earnings data on Tuesday, July, 29th. The company reported ($1.55) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $1.34. The firm had revenue of $1.74 million for the quarter, compared to analysts' expectations of $0.64 million. DBV Technologies had a negative trailing twelve-month return on equity of 287.15% and a negative net margin of 3,220.49%. When did DBV Technologies' stock split? DBV Technologies shares reverse split on the morning of Friday, November 29th 2024.The 1-5 reverse split was announced on Monday, November 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Meta Platforms (META), Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings7/29/2025Today8/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DBVT CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees80Year FoundedN/APrice Target and Rating Average Price Target for DBV Technologies$14.75 High Price Target$21.00 Low Price Target$7.25 Potential Upside/Downside+63.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($4.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$113.92 million Net Margins-3,220.49% Pretax Margin-3,217.23% Return on Equity-287.15% Return on Assets-138.83% Debt Debt-to-Equity RatioN/A Current Ratio2.45 Quick Ratio0.72 Sales & Book Value Annual Sales$4.15 million Price / Sales59.40 Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book2.86Miscellaneous Outstanding Shares27,390,000Free Float26,996,000Market Cap$246.51 million OptionableOptionable Beta-0.58 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:DBVT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.